Good post.
What's probably of more interest than the rise IN SAVA - NASDAQ is the Market cap of Cassava, which is fast approaching $1bn AUD. Exciting for ACW - ASX holders given Actinogen's Xanamem has the potential to treat close to a dozen neurological disorders including Alzhiemer's.
There is often a disparity between the Nasdaq and ASX biotechs but this does highlight what Actinogen Steven Gourlay has been stating for some time. If results in Actinogen's two current Phase 2 trial for both depression and AD replicate earlier clinical trials and continue to trend positively, as suggested by CMO Dana hilt, a significant rerate is on the cards ACW.
DYOR
- Forums
- ASX - By Stock
- Ann: ACW XanaCIDD depression trial results expected early August
Good post.What's probably of more interest than the rise IN SAVA...
-
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACW (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.6¢ |
Change
0.001(4.00%) |
Mkt cap ! $76.57M |
Open | High | Low | Value | Volume |
2.5¢ | 2.7¢ | 2.5¢ | $192.6K | 7.531M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 4201185 | 2.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.6¢ | 8694 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 4113185 | 0.025 |
23 | 6288803 | 0.024 |
25 | 5822139 | 0.023 |
14 | 8036010 | 0.022 |
18 | 2756880 | 0.021 |
Price($) | Vol. | No. |
---|---|---|
0.027 | 4207443 | 6 |
0.028 | 1031405 | 4 |
0.029 | 4642413 | 8 |
0.030 | 2614680 | 7 |
0.031 | 751771 | 3 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
ACW (ASX) Chart |